Literature DB >> 25808782

Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience.

Italo Bonadio1, Isabelle Colle, Anja Geerts, Peter Smeets, Giammauro Berardi, Marleen Praet, Xavier Rogiers, Bernard de Hemptinne, Hans Van Vlierberghe, Roberto I Troisi.   

Abstract

BACKGROUND: In patients with hepatocellular carcinoma (HCC), the outcome after liver transplantation (LT) is excellent if tumor characteristics are within the Milan criteria (MC). Expanded Asan criteria (AC) have not yet been validated in Western countries.
METHODS: A total of 76 patients with HCC underwent LT. Patients were divided and compared according to Milan, UCSF, and Asan criteria. Differences between pre- and post-operative assessment were evaluated. Overall survival (OS) and disease-free survival (DFS) were compared between groups. Predictors of recurrence were investigated.
RESULTS: Asan criteria provided 26% and 15% more criteria-fitting patients than MC and UCSF pre-operatively while 49% and 35% at pathological evaluation. Discrepancy between pre- and post-operative evaluation was 32% for MC, 33% for UCSF, and 18% for AC (p = 0.06). After a median follow-up of 70.5 months, patients exceeding MC but fulfilling Asan had comparable 5-yr OS and DFS to patients fulfilling MC (p = 0.17; p = 0.29). Patients exceeding UCSF but fulfilling AC had comparable 5-yr OS and DFS to patients fulfilling UCSF (p = 0.26; p = 0.32). Number of nodules, macro-vascular invasion, capsular invasion, and exceeding AC predicted recurrence at multivariate analysis (p = 0.01, 0.03, 0.01, 0.02, respectively).
CONCLUSIONS: The extension to AC allows increasing the number of patients eligible for LT without affecting OS and DFS.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Asan criteria; Milan criteria; UCSF criteria; expanded criteria; hepatocellular carcinoma; liver transplantation

Mesh:

Year:  2015        PMID: 25808782     DOI: 10.1111/ctr.12534

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  9 in total

1.  Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma.

Authors:  Zhijun Zhu
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

2.  Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0.

Authors:  Savio G Barreto; Simone I Strasser; Geoffrey W McCaughan; Michael A Fink; Robert Jones; John McCall; Stephen Munn; Graeme A Macdonald; Peter Hodgkinson; Gary P Jeffrey; Bryon Jaques; Michael Crawford; Mark E Brooke-Smith; John W Chen
Journal:  Cancers (Basel)       Date:  2022-06-03       Impact factor: 6.575

Review 3.  Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation.

Authors:  Helena Degroote; Anja Geerts; Xavier Verhelst; Hans Van Vlierberghe
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

4.  Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes.

Authors:  Robert Mahn; Farsaneh Sadeghlar; Alexandra Bartels; Taotao Zhou; Tobias Weismüller; Patrick Kupczyk; Carsten Meyer; Florian C Gaertner; Marieta Toma; Tim Vilz; Petra Knipper; Tim Glowka; Steffen Manekeller; Jörg Kalff; Christian P Strassburg; Maria A Gonzalez-Carmona
Journal:  Medicine (Baltimore)       Date:  2021-09-24       Impact factor: 1.817

5.  Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Jorge Henrique Bento de Sousa; Igor Lepski Calil; Francisco Tustumi; Douglas da Cunha Khalil; Guilherme Eduardo Gonçalves Felga; Rafael Antonio de Arruda Pecora; Marcio Dias de Almeida
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

6.  The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer.

Authors:  Michał Grąt; Karolina M Wronka; Jan Stypułkowski; Emil Bik; Maciej Krasnodębski; Łukasz Masior; Zbigniew Lewandowski; Karolina Grąt; Waldemar Patkowski; Marek Krawczyk
Journal:  Ann Surg Oncol       Date:  2016-08-16       Impact factor: 5.344

7.  LIVER TRANSPLANTATION FOR CARCINOMA HEPATOCELLULAR IN SÃO PAULO: 414 CASES BY THE MILAN/BRAZIL CRITERIA.

Authors:  Gustavo Pilotto D Sá; Fernando P P Vicentine; Alcides A Salzedas-Netto; Carla Adriana Loureiro de Matos; Luiz R Romero; Dario F P Tejada; Paulo Celso Bosco Massarollo; Gaspar J Lopes-Filho; Adriano M Gonzalez
Journal:  Arq Bras Cir Dig       Date:  2016 Nov-Dec

Review 8.  Expanding Indications for Liver Transplant: Tumor and Patient Factors.

Authors:  Kevin Ka-Wan Chu; Kelly Hiu-Ching Wong; Kenneth Siu-Ho Chok
Journal:  Gut Liver       Date:  2021-01-15       Impact factor: 4.519

9.  Hepatocellular carcinoma recurrence in living and deceased donor liver transplantation: a systematic review and meta-analysis.

Authors:  Hai-Ming Zhang; Yue-Xian Shi; Li-Ying Sun; Zhi-Jun Zhu
Journal:  Chin Med J (Engl)       Date:  2019-07-05       Impact factor: 2.628

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.